Overall verdict
Buy
7.3/10
1-year performance
-13.04%
Score breakdown
Down 13.0% over 1 year, 18% of the 52-week range.
Strongest: Financial strength 10.0/10. Weakest: Shareholder return 4.5/10.
26 analysts, target +0.4% vs the price.
Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing, commercializing, distributing, and selling of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, cold chain storage and shipping, and regulatory support services ;
and quality services and analytical testing services, such as IPC and release testing, stability study and testing, environmental monitoring, biosafety testing, as well as manufactures drug substance. In addition, it engages in the development and manufacture of antibody-drug conjugates and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.
Sector
Health Care
Industry
Life Sciences Tools and Services
Primary listing
Krx
South Korea
CEO
Mr. John Chongbo Rim
Founded
2011
Employees
5 455
Revenue / employee
835M KRW
Next earnings
October 21, 2026 (estimated)
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
1987000.00 KRW
52-week low
1228000.00 KRW
1-year performance
-13.04%
Declining
Year-to-date performance
-19.41%
Declining
Drawdown
-31.25%
Major drawdown
Position in the 52-week range
18% of range
Range: 988536.42 KRW - 1216327.90 KRW (2 methods agree)
The price implies growth of 14.57% per year; the company grows at 25.00%.
Gross margin 55.5%, net margin 39.9%, ROIC 16.6%, ROE 18.2%.
Net margin
39.90%
Exceptional
Sector 5.47%|S&P 12.97%
Gross margin
55.54%
High
Return on equity (ROE)
18.17%
Exceptional
Sector 3.01%|S&P 16.52%
Return on invested capital (ROIC)
16.60%
Exceptional
Free cash flow margin (FCF)
35.81%
Exceptional
Profit-to-cash conversion (FCF conversion)
0.90x
High
Margin stability
30.0 pts
Very uneven
Revenue to net income
Growth
5.0/10Revenue up 30.2% over 1 year, 31.4% a year over 5, EPS 36.9% a year over 5.
Revenue (trailing 12 months)
4.2T KRW
Revenue growth (1y)
30.24%
Hyper-growth
Revenue growth (3y)
51.83%
Strong
EPS growth (1y)
32.91%
Strong
EPS CAGR (5y)
36.88%
Exceptional
EPS revisions (3 months)
2.18%
Revised up
Valuation
6.5/10P/E 31.8x, forward P/E 33.5x, EV/EBITDA 26.8x, PEG 0.86. The multiple sits in the 3th percentile of its own 5-year history.
P/E (TTM)
31.8x
Fair
Sector 51.0x|S&P 23.0x
Forward P/E
33.5x
Expensive
EV / EBITDA
26.8x
Fair
Sector 28.3x|S&P 14.5x
PEG
0.86
Growth unpriced
Sector 0.12|S&P 0.86
Fair value (reverse DCF)
1211905.57 KRW
Overvalued
P/E vs its own 5-year history
among the 3% lowest valuations
Far cheaper than usual
Market cap
62.9T KRW
Financial strength
10.0/10Cash covers 176.3% of the debt, net debt/EBITDA -0.2x.
Net debt / EBITDA
-0.2x
Very solid
Gearing (net debt / equity)
-11.33%
Net cash
Cash
2.0T KRW
Cash / market cap
3.24%
Tight
Cash / total debt
176.32%
Net cash
Net debt
-881Md KRW
Equity
7.8T KRW
Closed daily candles, 2 years
Last close on September 23, 2026: 1,366,000.00 KRW
- MM201,446,650.00
- MM501,478,600.00
- MM2001,555,905.00
- RSI 1433.2
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-1.68%
200-day average slope, 3 months
-3.12%
50-day average slope, 1 month
+2.27%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
1.76 % per day
Volatility change
-33.87%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 40822.61 (4) | 40822.61 (4) | 5 468 298 (6) | 2 903 065 (5) | 1 899 430 (17) |
| 2027 | 48001.46 (4) | 48095.37 (5) | 6 370 150 (5) | 3 349 183 (4) | 2 279 477 (17) |
Amounts in millions of KRW, EPS in KRW per share. In brackets, the number of analysts. Consensus as of September 20, 2026.
Same sub-industry: 103 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 603259 | 8.0 | 8.0 | 75.1Md USD | 22.2x | 40.2 % | 47.7 % | 29.5 % | -1.7x | 2.6 % | 56.1 % | ||
| 2 | A207940 | 7.3 | 7.2 | 46.0Md USD | 31.8x | 39.9 % | 30.2 % | 16.6 % | -0.2x | 2.4 % | -13.0 % | ||
| 3 | IQV | 6.8 | 7.0 | 44.1Md USD | 33.2x | 8.1 % | 8.8 % | 6.8 % | 4.1x | 5.0 % | 47.6 % | ||
| 4 | DHR | 6.4 | 6.5 | 156Md USD | 39.3x | 15.9 % | 5.5 % | 5.4 % | 2.0x | 3.5 % | 18.6 % | ||
| 5 | A | 6.3 | 6.5 | 46.6Md USD | 32.5x | 19.5 % | 8.1 % | 13.9 % | 0.9x | 2.7 % | 38.1 % | ||
| 6 | LONN | 6.3 | 6.1 | 46.4Md USD | Not meaningful (loss) | 16.7 % | 19.2 % | 8.7 % | 1.9x | 0.6 % | 6.1 % | ||
| 7 | TMO | 5.9 | 5.7 | 246Md USD | 35.8x | 15.0 % | 10.5 % | 7.9 % | 2.8x | 3.0 % | 45.0 % | ||
| 8 | ILMN | 4.6 | 4.6 | 38.6Md USD | 47.6x | 18.4 % | 9.8 % | 18.2 % | 0.8x | 2.4 % | 175.3 % | ||
| 9 | WAT | 4.5 | 3.3 | 41.3Md USD | 105.0x | 3.6 % | 113.3 % | 1.4 % | 0.8x | 0.9 % | 44.7 % |
